论文部分内容阅读
目的:探究吉非替尼联合平消胶囊治疗中晚期非小细胞肺癌(NSCLC)的临床疗效及安全性。方法:选取2014年1月~2015年5月青海大学附属医院收治的70例中晚期NSCLC患者作为研究对象,经数字表法将之均分为观察组与对照组各35例,观察组行吉非替尼联合平消胶囊治疗,对照组行单纯吉非替尼治疗。比较两组患者客观疗效、生存质量以及不良反应发生情况。结果:治疗后观察组生存质量改善率显著高于对照组,血清IgG、IgA、IgM显著高于对照组,外周血CD3、CD4~+、CD4~+/CD8~+和CD8~+显著高于对照组,消化道反应发生率显著低于对照组(P<0.05);两组治疗有效率和疾病控制率差异无统计学意义(P>0.05)。结论:吉非替尼联合平消胶囊治疗中晚期NSCLC能有效提高患者的生存质量和免疫功能,减少不良反应发生率。
Objective: To explore the clinical efficacy and safety of gefitinib combined with Pingxiao capsule in the treatment of advanced non-small cell lung cancer (NSCLC). METHODS: A total of 70 patients with advanced NSCLC admitted to the Affiliated Hospital of Qinghai University from January 2014 to May 2015 were selected as study subjects. They were divided into observation group and control group with 35 cases each by digital table method. The observation group was OK. The patients were treated with fenfinib and Pingxiao capsule, and the control group was treated with gefitinib alone. Objective efficacy, quality of life, and incidence of adverse reactions were compared between the two groups. Results: The improvement rate of quality of life in the observation group after treatment was significantly higher than that in the control group. Serum IgG, IgA and IgM were significantly higher than those in the control group. CD3, CD4+, CD4+/CD8+ and CD8+ were significantly higher in the peripheral blood than in the control group. The incidence of digestive tract reaction in the control group was significantly lower than that in the control group (P<0.05); there was no significant difference in the treatment efficiency and disease control rate between the two groups (P>0.05). Conclusion: Gefitinib combined with Pingxiao capsule treatment of advanced NSCLC can effectively improve the patient’s quality of life and immune function, reduce the incidence of adverse reactions.